Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 08, 2021 10:17 ET | Source: Cerevance

Neuroscience Drug Development Veteran Mike Poole, M.D., FACP, to Join Cerevance Board of Directors

BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cerevance, a private clinical-stage drug discovery and development company focused on brain diseases, today announced the appointment of Mike Poole, M.D.,...
February 10, 2021 10:17 ET | Source: Cerevance

Cerevance Appoints Naidong Ye, Ph.D., As Vice President and Head of Chemistry, Manufacturing and Controls

BOSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of Naidong Ye, Ph.D., a seasoned...
February 01, 2021 10:17 ET | Source: Cerevance

Cerevance Appoints Carrie Ann Cook As Chief Business Officer

BOSTON, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of Carrie Ann Cook, a global business...
December 08, 2020 10:17 ET | Source: Cerevance

Cerevance Appoints David Lubner to Board of Directors

BOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of David Lubner, a senior finance...
November 16, 2020 10:17 ET | Source: Cerevance

Cerevance’s CVN058 Achieves Primary Endpoint in Phase Ib Schizophrenia Cognition Study

BOSTON, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, today announced positive results from a Phase 1b clinical trial...
July 21, 2020 10:17 ET | Source: Cerevance

Cerevance Expands Series B Financing to $65 Million

BOSTON, July 21, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, has expanded its Series B financing round, adding $20 million to the...
April 14, 2020 10:17 ET | Source: Cerevance

Cerevance Closes $45 Million Series B Financing

BOSTON, MA, April 14, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, has closed a Series B financing, bringing in $45 million from...
February 03, 2020 10:17 ET | Source: Cerevance

Cerevance to Present at the BIO CEO & Investor Conference

BOSTON, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, today announced the company will present at the BIO CEO...